1 Broadway # 14, Cambridge, MA 02142
The first indication for SDX-7320 is in post-menopausal HR+/Her2- metastatic breast cancer in combination with standard of care treatment. We are currently planning on starting this Phase 1b combination safety trial in late 2017.
Clinical trials for other indications (e.g. metastatic colorectal and prostate) will follow.